UCL Prostate Cancer Research Centre

UCL Prostate Cancer Research Centre

• Home
• Research
• People
  • John Masters
  • Aamir Ahmed
  • Magali Williamson
  • Maria Notara
  • Charlotte Beaver
  • Reena Davda
  • Ali Atta-Ul
  • Adebiyi Damola
  • Anne Legendre
  • Achim Newrzella
• Seminars and Events
• Contact Us
• Support Us
• About Us
• Videos

Professor John Masters PhD FRCPath FRCR (Hon)

Professor of Experimental Pathology

Prostate Cancer Research Centre
Research Department of Urology
Charles Bell House
Room: 3.03
67-73 Riding House Street
W1W 7EJ

E-mail: j.masters@ucl.ac.uk
Tel: 020 7679 9543

Research interests

Urological Cancers, stem cells, human cell culture, cancer research

External commitments

Editor in Chief for Cell Biology and Toxicology
Chairman of ATCC Standard Development on the Authentication of Human Cells
Scientific consultant for the Ovarian and Prostate Cancer Trust
Chief Executive of the Prostate Cancer Research Centre

Selected publications (since 2000)

American Type Culture Collection Standards Development Organisation Workgroup ASN0002. Cell line misidentification: the beginning of the end. Nature Reviews Cancer 10, 441-448, 2010

Wang Q, Symes AJ, Kane CA, Freeman A, Nariculam J, Munson P, Thrasivoulou C, Masters JRW, Ahmed A. A novel role for Wnt/Ca2+ signaling in actin cytoskeleton remodelling and cell motility in prostate cancer. Plos One 5, e10456, 2010.

Young L, Sung J, Stacey G, Masters JR. Detection of Mycoplasma in cell cultures. Nature Protocols 5: 929-934, 2010.

Wells CM, Whale AD, Parsons M, Masters JRW, Jones GE. PAK4: a pluripotent kinase that regulates prostate cancer cell adhesion. J Cell Sci 123: 1663-1673, 2010.

Masters JRW, Palsson BO. Human Cell Culture Volume 7. Human adult stem cells. Springer, Dordrecht, 2009

Stacey N and Masters JRW. Cryopreservation and banking of mammalian cell lines. Nature Protocols 3: 1981-1989, 2008.

Masters JR, Kane C, Yamamoto H, Ahmed A. Prostate cancer stem cell therapy: hype or hope? Prostate Cancer and Prostatic Diseases, 11: 316-319, 2008

James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Anderson J, Popert RJ, Sanders K, Morgan RC, Stansfeld J, Dwyer J, Masters J, Parmar MKB. STAMPEDE: Systemic therapy for advancing or metastatic prostate cancer - a multi-arm multi-stage randomised controlled trial. Clinical Oncology 20: 577-581, 2008

Ahmed T, Shea K, Masters JRW, Jones GE, Wells CM. A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF. Cell Signalling 20: 1320-1328, 2008.

Hastie C, Masters JR, Moss SE, Naaby-Hansen S. IFN-γ reduces cell surface expression of annexin 2 and suppresses the invasive capacity of prostate cancer cells. J Biol Chem 283: 12595-12603, 2008.

Masters JRW, Palsson BO and Thomson JA. Human Cell Culture Volume 6. Human embryonic stem cells. Springer, Dordrecht, 2007.

Wong OGW, Nitkunan T, Oinuma I, Zhou C, Blanc V, Brown RSD, Bott SRJ, Nariculam J, Box G, Munson P, Constantinou J, Feneley M, Klocker H, Eccles SA, Negishi M, Freeman A, Masters JR, Williamson M. Plexin-B1 mutations in prostate cancer. Proc National Academy Sciences 104: 19040-19045, 2007.

Masters JR and Stacey GN. Changing medium and passaging cell lines. Nature Protocols 2, 2276-2284, 2007.

Wang Q, Williamson M, Bott S, Brookman-Amissah N, Freeman A, Nariculam J, Ahmed A, Masters JR. Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene, 26: 6560-6565, 2007.

Daly-Burns B, Alam TN, Mackay A, Clark J, Shepherd CJ, Rizzo S, Tatoud R, O'Hare MJ, Masters JR, Hudson DL. A conditionally immortalized cell line model for the study of human prostatic epithelial cell differentiation. Differentiation 74: 1-14, 2006.

Hastie C, Saxton M, Akpan A, Cramer R, Masters JR and Naaby-Hansen S. Combined affinity labelling and mass spectrometry analysis of differential cell surface protein expression in normal and prostate cancer cells. Oncogene 24: 5905-5913, 2005.

Birtle AJ, Freeman A, Masters JRW, Payne HA, Harland SJ. Tumour markers for managing men who present with metastatic prostate cancer and serum prostate-specific antigen levels of <10ng/mL. BJU Int 96: 303-307, 2005.

Nagano K, Masters JR, Akpan A, Yang A, Corless S, Wood C, Hastie C, Zvelebil M, Cramer R and Naaby-Hansen S. Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and II interferons. Oncogene 23, 1693 - 1703, 2004.

Masters JR and Köberle B. Curing metastatic cancer: lessons from testicular germ-cell tumours. Nature Cancer Reviews 3: 517-525, 2003.

Masters JRW, Vani UD, Grigor KM, Griffiths GO, Crook A, Parmar MKB, Knowles MA. Can p53 staining be used to identify patients with aggressive superficial bladder cancer? J Pathol 200: 74-81, 2003

Brown RSD, Edwards J, Dogan A, Payne H, Harland SJ, Bartlett JMS, Masters JRW. Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. J Pathol 198: 237-244, 2002.

Masters JRW. Hela cells 50 years on: the good, the bad and the ugly. Nature Reviews Cancer 2: 315-319, 2002.

Masters JRW. Methods to improve the efficacy of intravesical mitomycin C: results of a randomized phase III trial. Journal of the National Cancer Institute 93: 1574-1575, 2001.

Masters JRW, Thomson JA, Daly-Burns B, Reid YA, Dirks W, Packer P, Toji LH, Ohno T, Tanabe H, Arlett CF, Kelland LR, Harrison M, Virmani A, Ward TH, Ayres KG, Debenham PG. STR profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci USA 98: 8012-8017, 2001.

Masters JRW. Cancer cell lines. Nature Reviews Molecular Cell Biology 1: 233-236, 2000.

Hudson DL, O'Hare MJ, Watt FM and Masters JRW. Proliferative heterogeneity in the human prostate: evidence for epithelial stem cells. Lab Invest 80: 1243-1250, 2000.

Masters JRW and Lakhani SR. How microarrays can help cancer patients. Nature 404: 921, 2000.

Stacey GN, Masters JRW, Hay RJ, Drexler HG, MacLeod RAF, Freshney RI. Cell contamination leads to inaccurate data: we must take action now. Nature 403: 356, 2000.